Average Co-Inventor Count = 12.30
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Signal Pharmaceuticals, Inc. (14 from 169 patents)
2. Effector Therapeutics, Inc. (4 from 21 patents)
3. Abbott Laboratories Corporation (1 from 4,177 patents)
4. Lycia Therapeutics, Inc. (1 from 1 patent)
20 patents:
1. 12258332 - ASGPR cell surface receptor binding compounds and conjugates
2. 11440917 - EIF4A-inhibiting compounds and methods related thereto
3. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
4. 11286268 - EIF4E-inhibiting compounds and methods
5. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
6. 10577378 - EIF4A-inhibiting compounds and methods related thereto
7. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
8. 9957277 - eIF4A-inhibiting compounds and methods related thereto
9. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
10. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors
11. 9079900 - Methods of synthesis and purification of heteroaryl compounds
12. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
13. 8569494 - Methods of synthesis and purification of heteroaryl compounds
14. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
15. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway